Key points from article :
Maxwell Biosciences announced publication of a revolutionary mechanism of action study for their Claromer compounds.
These novel molecules inactivates several viruses, including Influenza, Coronavirus, Hepatitis, Herpes, Zika and Chikungunya strains.
Claromers disrupt the pathogen membrane, opening up a promising new avenue for combating infectious diseases.
"...disrupting the membrane that surrounds human viruses is a promising mechanism for developing new antivirals," - Kent Kirshenbaum, study's senior author.
Claromers possess novel mechanism, broad-acting efficacy, resistance prevention, no adverse effect on commensal microbiome.
Reveals the potential for the Claromers to combat bacterial and fungal pathogens simultaneously.
Combating currently untreatable infectious diseases drives their first target clinical indication, multi-pathogenic Chronic Rhinosinusitis.
Claromers act selectively against pathogens relevant to chronic sinusitis, while sparing healthy human cells.
Approach may lead to many anti-viral drugs, and help overcome challenges with antimicrobial drug resistance.
Ongoing studies aim to evaluate the full potential of these revolutionary molecules in treating human disease.
Study by Maxwell Biosciences and NYU, published in ACS Infectious Diseases.
